The incoming CEO of Roche says he hopes that the company's partnership with Alnylam will create a "second Genentech" in the U.S. for the pharma giant. Alnylam opens up a "new front" in biotech, says Severin Schwan. Roche is paying $331 million up front to gain access to Alnylam's drug discovery technology. It's another sign of the steady convergence of biotech and pharma, with a product-hungry pharma world looking to biotechnology companies to supply the products of the future. It's also a key indicator of the thriving market for new deals.
- read the AFX report for more information
Relate Articles:
Roche shakes up R&D, eyes new buyouts. Report
Roche harnesses Alnylam's RNAi tech in $1B deal. Report
Genentech touts pipeline as doubts fester. Report